Transplantation of Peripheral Blood Stem Cells as Compared With Bone Marrow From HLA-Identical Siblings in Adult Patients With Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia

Ringdén, Olle; Labopin, Myriam; Bacigalupo, Andrea; Arcese, William; Schaefer, U. W.; Willemze, R.; Koç, Hakan; Bunjes, Donald; Gluckman, Éliane; Rocha, Vanderson; Schattenberg, A; Frassoni, Francesco

doi:10.1200/jco.2002.12.049

Cited by 135 publications

(123 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…More than half our patients are transplanted from unrelated donors 6,10 and more than half of our patients receive peripheral stem cells rather than bone marrow grafts. 11,12 More recently, nonmyeloablative conditioning has been introduced and is now used in many SCT patients. 13 Therefore, we wanted to repeat our previous study and analyze the impact of these new transplant modalities on the likelihood to become seronegative and to lose protective immunity against measles.…”

Section: Discussionmentioning

confidence: 99%

Measles immunity after allogeneic stem cell transplantation; influence of donor type, graft type, intensity of conditioning, and graft-versus host disease

Ljungman

Aschan

Barkholt

et al. 2004

Bone Marrow Transplant

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Measles immunity after allogeneic stem cell transplantation; influence of donor type, graft type, intensity of conditioning, and graft-versus host disease

Ljungman

Aschan

Barkholt

et al. 2004

Bone Marrow Transplant

View full text Add to dashboard Cite

“…1 Compared with bone marrow (BM) grafts, PBSC contain significantly more CD34 þ hematopoietic stem cells, as well as 1 log more T-lymphocytes. 2 Although allogeneic PBSC is associated with faster myeloid and immune reconstitution, concerns about the incidence of chronic GVHD (cGVHD) and the associated related morbidity and mortality still exist, especially for patients with low-risk diseases and low probability of relapse post-transplantation.…”

Section: Introductionmentioning

confidence: 99%

The number of infused CD34+ cells does not influence the incidence of GVHD or the outcome of allogeneic PBSC transplantation, using reduced-intensity conditioning and antithymocyte globulin

Tsirigotis

Shapira

et al. 2009

Bone Marrow Transplant

View full text Add to dashboard Cite

The influence of graft composition on the outcome of reduced-intensity (RIC) allogeneic PBSC transplantation (allo-PBSC) remains controversial. In this study, we analyzed the impact of CD34 þ cell dose on the incidence of GVHD, and on the outcome after allo-PBSC, in 103 patients with hematological malignancies, using a uniform RIC regimen. The following variables were included in statistical analysis: (1) number of C34 þ cells, (2) highrisk vs low-risk disease status, (3) matched related vs matched unrelated donor, (4) female donor to male recipient vs any other combination, (5) age of recipient (above vs below the median). Univariate and multivariate analysis did not reveal any association between CD34 þ cell dose and acute grade-2 to grade-4, cGVHD, nonrelapse mortality (NRM), relapse rate (RR) and OS. High-risk disease status was the only variable independently associated with increased NRM (P ¼ 0.001), increased RR (P ¼ 0.012) and decreased OS (Po0.001). The same results were obtained when analysis was restricted to a subgroup of 55 patients with myeloid neoplasms. The influence of graft composition on the outcome of RIC allo-PBSC should be further investigated via well-controlled randomized prospective studies.

show abstract

“…27,28 Expanded use of reduced intensity regimens may also increase the availability of allogeneic transplantation for older patients with highrisk AML. 29,30 Because patients in our CALGB cohort had a median age of 45 years, allogeneic transplantation with conventional or reduced intensity conditioning for patients with t(6;11) AML may be feasible, as has been explored in one small study. 24 However, the role of allogeneic transplantation for patients with specific chromosomal abnormalities deemed to have adverse prognostic significance is unclear.…”

Section: Discussionmentioning

confidence: 99%

Adult de novo acute myeloid leukemia with t(6;11)(q27;q23)

Blum

Mrózek

Ruppert

et al. 2004

Cancer

View full text Add to dashboard Cite

BACKGROUND Acute myeloid leukemia (AML) with t(6;11)(q27;q23) is a well established but rare entity, and few studies have reported the full clinical, hematologic, and outcome data of patients with this disease. METHODS To characterize the features of t(6;11) AML, the authors searched the Cancer and Leukemia Group B (CALGB) cytogenetic database comprising 2667 adults with newly diagnosed, de novo AML and identified 16 patients (0.6%) with t(6;11). A review of the literature identified 33 adults with de novo t(6;11) AML for whom survival data were available. RESULTS CALGB patients had a median age of 45 years (range, 22–65 years) and commonly presented with French–American–British (FAB) subtype M4 or M5 (81%). Gingival involvement at presentation was common (31%). All patients with gingival involvement had FAB M4. Compared with other patients with M4 AML in the CALGB database (n = 429), patients with M4 and t(6;11) (n = 7) had a higher frequency of gingival hypertrophy at presentation (71% vs. 17%, P = 0.003). Patients with t(6;11) were more likely to be African American (P = 0.02) and to die during induction (P = 0.03) than those without t(6;11). The complete response (CR) rate was 69% (11 of 16 patients), and CR duration was short (median, 9 months). The estimated probability of 2‐year survival was 13%. Both long‐term survivors received allogeneic stem cell transplantation. The estimated probability of 2‐year survival of patients reported in the literature was 15%. CONCLUSIONS Although the patient sample was small, the authors suggested that investigational approaches, including allogeneic transplantation, be considered for adults with t(6;11) AML. Cancer 2004. © 2004 American Cancer Society.

show abstract

Transplantation of Peripheral Blood Stem Cells as Compared With Bone Marrow From HLA-Identical Siblings in Adult Patients With Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia

Abstract: Allogeneic PBSC results in faster neutrophil and platelet engraftment and a higher incidence of chronic GVHD than BM. However, acute GVHD, TRM, relapse, survival, and LFS were similar in patients receiving PBSCs versus BM.

Cited by 135 publications

References 29 publications

Measles immunity after allogeneic stem cell transplantation; influence of donor type, graft type, intensity of conditioning, and graft-versus host disease

Measles immunity after allogeneic stem cell transplantation; influence of donor type, graft type, intensity of conditioning, and graft-versus host disease

The number of infused CD34+ cells does not influence the incidence of GVHD or the outcome of allogeneic PBSC transplantation, using reduced-intensity conditioning and antithymocyte globulin

Adult de novo acute myeloid leukemia with t(6;11)(q27;q23)

Contact Info

Product

Resources

About